Cancer is fundamentally a disease of uncontrolled cell division. In healthy tissue, cells follow a tightly regulated cycle of growth, DNA copying, and division, with built-in checkpoints that halt the process if something goes wrong. Cancer cells break through these checkpoints, dividing when they shouldn’t and ignoring signals that would normally stop them. The result is a population of cells that multiplies relentlessly, forming tumors or flooding the bloodstream.
How the Normal Cell Cycle Works
Every cell that divides passes through four main phases. In G1, the cell grows and prepares to copy its DNA. In S phase, it duplicates all of its genetic material. In G2, it checks that the copy is accurate and gears up for division. In M phase (mitosis), it physically splits into two daughter cells. Between these phases sit three critical checkpoints that act like quality-control gates.
The G1/S checkpoint, sometimes called the restriction point, decides whether the cell should commit to dividing at all. It checks for adequate size, nutrients, and the right growth signals from neighboring cells. The G2/M checkpoint, often called the DNA damage checkpoint, verifies that DNA replication finished correctly before mitosis begins. The spindle assembly checkpoint operates during mitosis itself, confirming that chromosomes are properly attached to the cellular machinery that pulls them apart. If any checkpoint detects a problem, the cycle pauses until the issue is fixed, or the cell is directed to self-destruct.
How Cancer Cells Override Checkpoints
Cancer cells don’t invent a new way to divide. They hijack the existing machinery by altering the levels or function of the proteins that run it. The most common strategy is ramping up the accelerators while disabling the brakes.
At the G1/S checkpoint, progression depends on protein complexes that tag a key gatekeeper protein (called Rb) for inactivation, releasing the cell into S phase. In many tumor types, the accelerator complexes that perform this tagging are abnormally elevated, pushing cells past the restriction point even without proper growth signals. This particular abnormality shows up across a wide range of cancers, from breast to lung to melanoma.
At the G2/M checkpoint, a signaling pathway normally senses DNA damage and blocks the cell from entering mitosis until repairs are made. When the proteins in this pathway are dysregulated, cells with damaged or incompletely copied DNA slip into division anyway. That damaged DNA gets passed to daughter cells, accumulating mutations with each generation and accelerating the cancer’s evolution.
The spindle assembly checkpoint relies on a group of sensor proteins that detect whether chromosomes are correctly lined up before the cell splits. Mutations in these sensor proteins allow cells to divide even when chromosomes aren’t properly sorted, producing daughter cells with the wrong number of chromosomes. This chromosomal instability is a hallmark of aggressive tumors.
The Role of Oncogenes and Growth Signals
Normal cells wait for external growth signals before entering the cell cycle. Cancer cells often short-circuit this requirement. One of the best-understood examples involves a protein called Ras, which sits at the top of a signaling chain that tells the cell to start dividing. When Ras is permanently switched on by a mutation, it triggers two things simultaneously: it boosts production of the proteins that push the cell through G1, and it destroys a brake protein that normally keeps the cell quiet. The brake protein is broken down through the cell’s own recycling system, so the cell loses its ability to stay in a resting state.
The net effect is a cell that behaves as though it’s constantly receiving “divide now” signals from its environment, even when no such signals exist. Ras mutations appear in roughly a quarter of all human cancers.
Tumor Suppressors: The Broken Brakes
If oncogenes are stuck accelerators, tumor suppressors are the braking system. The most important one is p53, often called the “guardian of the genome.” When DNA is damaged, p53 activates genes that halt the cell cycle, giving repair machinery time to fix the problem. If the damage is too severe, p53 triggers programmed cell death.
Roughly half of all human cancers carry a mutation in p53. Without functional p53, cells with damaged DNA sail through the G1/S checkpoint unchecked. They accumulate genetic errors at a much faster rate, which in turn creates more mutations in other cell cycle genes. This is why p53 loss is often an early and pivotal event in cancer development: it opens the door for a cascade of further genetic damage.
Other brake proteins work at different points in the cycle. Some directly block the accelerator complexes at G1, preventing them from pushing the cell forward. When the genes encoding these inhibitors are silenced or deleted, the cell loses another layer of protection against uncontrolled division.
How Fast Cancer Cells Actually Divide
A common assumption is that cancer cells divide extraordinarily fast, but the reality is more nuanced. Laboratory measurements of 60 different cancer cell lines show cycle times ranging from about 17 to 80 hours. Some cancer cells complete a full division in less than a day; others take more than three days. What makes cancer dangerous isn’t always raw speed. It’s that the cells never stop. Normal cells exit the cycle and enter a resting state when they receive the right signals. Cancer cells ignore those signals and keep cycling.
Pathologists measure this continuous cycling using a marker called Ki-67, a protein present only in cells that are actively dividing. In breast cancer, a Ki-67 labeling index above 10 to 14 percent generally identifies a higher-risk tumor. An international expert panel classifies breast tumors as low proliferation (15 percent or below), intermediate (16 to 30 percent), or highly proliferating (above 30 percent). Higher Ki-67 values often influence treatment decisions, such as whether chemotherapy should be added to hormone therapy.
Therapies That Target the Cell Cycle
Understanding exactly where cancer cells break the rules has led to drugs designed to restore specific checkpoints. The most successful examples so far are inhibitors that block the accelerator complex responsible for pushing cells through G1. Three of these drugs were approved by the FDA between 2015 and 2017, and they have become a cornerstone of treatment for hormone receptor-positive breast cancer. A newer combination therapy received approval in 2024 for patients whose tumors developed resistance to earlier treatments.
These drugs work by reactivating the G1/S checkpoint, effectively reinstalling the brake that cancer cells had disabled. The cell gets stuck in G1 and can no longer copy its DNA or divide. Because the drugs target a specific molecular vulnerability rather than killing all dividing cells indiscriminately, they tend to cause fewer side effects than traditional chemotherapy, which poisons any rapidly dividing cell in the body, healthy or not.
Research into drugs targeting the G2/M checkpoint and the spindle assembly checkpoint is also underway, with the goal of creating therapies for cancers that rely on bypassing those later gates.
Why Multiple Mutations Matter
Cancer rarely results from a single broken gene. Most tumors accumulate mutations in several cell cycle regulators over time. A cell might first lose p53, allowing DNA damage to go unrepaired. Then a growth-signaling gene like Ras gets stuck in the “on” position. Later, the genes encoding checkpoint brake proteins get silenced. Each mutation peels away another layer of control, and the cell becomes progressively more autonomous and harder to stop.
This stepwise accumulation explains why cancer risk increases with age. Each cell division carries a small chance of introducing a new mutation, and over decades those chances add up. It also explains why cancers with more mutations tend to be more aggressive: they’ve disabled more safeguards, so they cycle faster, tolerate more DNA damage, and adapt more readily to therapies that target only one vulnerability.